Jaguar Health Shares Spike After 816% Revenue Jump, But Trial Results Still Key
Jaguar Health Inc. shares rose Wednesday as the small drugmaker posted an 816% surge in first-quarter revenue. The bump came after a licensing deal that transferred U.S. commercial rights for Mytesi and Canalevia-CA1 to Woodward Specialty, which is linked to privately held Future Pak. Shares finished the day at $3.67, gaining 9.2% from $3.36 on Tuesday. Trading volume jumped to 593,152 shares from 69,266, Jaguar’s LSEG-based price table showed.